SEC filings
Edwards Lifesciences (EW)
Recent filings Edwards Lifesciences made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0001099800All filings on SEC.gov
10-QQuarterly report
Quarterly report
Edwards Lifesciences reported net sales of $5.105 billion for the first nine months of 2026, up 13.5% from a year earlier, driven by TAVR and TMTT products. …
8-KCurrent report
Results of Operations and Financial Condition
Edwards Lifesciences reported third-quarter 2026 sales of $1.72 billion, up 10.5% year over year, and raised its full-year 2026 sales and adjusted EPS guidance. …
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Edwards Lifesciences has received notice from Donald E. Bobo, Jr., Corporate Vice President, Strategy and Corporate Development, that he will retire from the company by mid-year 2027. …
10-QQuarterly report
Quarterly report
Edwards Lifesciences reported first-half 2026 net sales of $3.4 billion, up 15.1% year over year, driven primarily by its TAVR and TMTT product groups. …
8-KCurrent report
Results of Operations and Financial Condition
Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion, up 13.6% year over year, with TAVR sales of $1.26 billion and TMTT sales of $195.9 million; adjusted EPS was $0.78. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Edwards Lifesciences in Readster
Add Edwards Lifesciences to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.